FRANKFURT (Reuters) - Germany's Ratiopharm said on Friday it plans to launch a generic version of Sanofi-Aventis's blockbuster blood thinning drug Plavix soon. "Ratiopharm will soon offer the first ...

LONDON, July 29 (Reuters) - French drugmaker Sanofi-Aventis and its U.S. partner Bristol-Myers Squibb Co suffered a setback on Tuesday when a German court backed immediate marketing approval for ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

In the latest twist in the long-running battle between Sanofi-aventis and Bristol-Myers Squibb and Apotex, the originator drugs companies secured a preliminary injunction against the Canadian company ...

A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis.

Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY) now have the upper hand in an upcoming patent trial over their blockbuster heart drug Plavix, if Thursday’s court injunction in the case is any ...

BOSTON (MarketWatch) -- News that Bristol-Myers Squibb and partner Sanofi-Aventis may have successfully warded off early generic competition for their blockbuster drug Plavix stoked trading of drug ...

How the influx of generics is bad for drug makers but good for you. July 25, 2011— -- intro: Ten of the world's top-selling prescription drugs are about to get cheaper. Over the next 17 months, ...